Breaking News
January 16, 2019 - Neurons with good housekeeping are protected from Alzheimer’s
January 16, 2019 - Is mindfulness worthy of all the hype?
January 16, 2019 - Physical Activity, Any Type or Amount, Cuts Health Risk from Sitting
January 16, 2019 - New understanding in the evolution of human feet
January 15, 2019 - AHA: New Cholesterol Guidelines Put Ethnicity in the Spotlight
January 15, 2019 - Different brain areas linked to smoking and drinking
January 15, 2019 - Henry Marsh shares insights into neurosurgery and more at Dean’s Lecture Series
January 15, 2019 - Want to Live Longer? For Just 30 Minutes a Day, Do Anything Else But Sit
January 15, 2019 - The Current issue of “The view from here” is concerned with Targets
January 15, 2019 - Plain packaging sparked tobacco price rises, new study finds
January 15, 2019 - Sedentary lifestyles can be unhealthy, physical activity can lower risk
January 15, 2019 - Gut microbiome may help prevent development of cow’s milk allergy
January 15, 2019 - Lesbian, gay and bisexual individuals more likely to suffer severe substance use disorders
January 15, 2019 - New England Journal of Medicine Publishes Positive Results of the Pivotal Trial of Cablivi (caplacizumab) for Rare Blood Clotting Disorder
January 15, 2019 - Levels of inflammatory marker (CRP) linked to housing type and tenure
January 15, 2019 - Three gifts I’m glad I gave myself in 2018
January 15, 2019 - Columbia’s Pediatrics Department Names New Vice Chairs, Expands Leadership
January 15, 2019 - US FDA Accepts Regulatory Submissions for Review of Tafamidis to Treat Transthyretin Amyloid Cardiomyopathy
January 15, 2019 - Staying fit can cut your risk of heart attack by half
January 15, 2019 - Vitamin D supplements are of no gain to those over 70, study shows
January 15, 2019 - Scientists create comprehensive new method to predict breast cancer risk
January 15, 2019 - Research shows connection between social media use and impaired risky decision-making
January 15, 2019 - FDA Approves Expanded Use of Adacel (Tdap) Vaccine for Repeat Vaccination
January 15, 2019 - Treating spinal pain with replacement discs made of ‘engineered living tissue’ moves closer to reality
January 15, 2019 - Providers Walk ‘Fine Line’ Between Informing And Scaring Immigrant Patients
January 15, 2019 - Outcomes Poorer for Medicaid Beneficiaries With STEMI
January 15, 2019 - Decorative Products on Foods Can Be Unsafe
January 15, 2019 - A dream of sustainable surgery in Uganda
January 15, 2019 - Study shows how herpes viruses and tumors have learned to manipulate the same ancient RNA
January 15, 2019 - Common Heart, Diabetes Meds May Help Ease Mental Illness
January 15, 2019 - Stress and trauma in earliest years linked to reduced hippocampal volume in adolescence
January 15, 2019 - Scientists identify endogenous activator of sigma-1 receptors in human cells
January 15, 2019 - MAR treatments unlikely to be cause of premature or low birth weight babies
January 15, 2019 - Parental CPTSD increases transmission of trauma to offspring of Tutsi genocide survivors
January 15, 2019 - High-fat diets shown to increase blood pressure
January 15, 2019 - New institute for food safety to be established in Netherlands
January 15, 2019 - Keele University researchers receive £2.4 million grant to help reduce overprescribing of opioids
January 15, 2019 - Synthetic compound reverses mutant p53 aggregate accumulation, study shows
January 15, 2019 - First elder care robot tested in a WSU smart home apartment
January 15, 2019 - Oxford researchers explore relationship between technology use and adolescent mental health
January 15, 2019 - From microbiome research to healthier and sustainable foods
January 15, 2019 - How coaching moms and dads improves infants’ language skills
January 15, 2019 - Precision health approach tapped to identify causes of poverty
January 14, 2019 - DNA origami can accurately measure how antibodies interact with several antigens
January 14, 2019 - Researchers identify multiple new subtypes of most common childhood cancer
January 14, 2019 - Total Fertility Rates Vary by State
January 14, 2019 - Elevated blood lead level in early childhood associated with increased risk of academic problems in school-aged children
January 14, 2019 - Superior technique identified that can block CRISPR gene editing
January 14, 2019 - Turning breast cancer cells into fat cells prevents the formation of metastases
January 14, 2019 - Review examines what influences HIV-positive patients to stay on antiretroviral drugs in Africa
January 14, 2019 - Identifying genetic factors that lead to squamous cell carcinoma
January 14, 2019 - Virtual video visits can replace office visits without compromising quality of care
January 14, 2019 - Health Highlights: Jan. 10, 2019
January 14, 2019 - Molecular hallmarks of tumor hypoxia across 19 cancer types discovered
January 14, 2019 - Scientists uncover how protein clumps damage cells in Parkinson’s
January 14, 2019 - Physician-scientist’s “indomitable spirit” prevails over personal adversity
January 14, 2019 - King’s researchers receive £1.25 million to investigate fatal eating disorder
January 14, 2019 - UCR researchers uncover how plants sense temperature
January 14, 2019 - Scientists find link between colitis and colon cancer
January 14, 2019 - New skin patch provides long-acting contraceptive protection
January 14, 2019 - Asparagine synthetase deficiency – Genetics Home Reference
January 14, 2019 - Improved stem cell approach could aid fight against Parkinson’s
January 14, 2019 - New class of sleeping pill preserves ability to wake in response to danger signals
January 14, 2019 - Cancer patients are four times more likely to commit suicide
January 14, 2019 - The human brain works in reverse order to retrieve memories
January 14, 2019 - Simple tips can lead to better food choices
January 14, 2019 - Meth’s Resurgence Spotlights Lack Of Meds To Combat The Addiction
January 14, 2019 - TARA Biosystems and Insilico Medicine collaborate to discover novel therapies for cardiac disease
January 14, 2019 - Early life stress in mice affects their offspring behavior
January 14, 2019 - Depression Tied to Worse Asthma Outcomes in Urban Teens
January 14, 2019 - Santa calorie counting
January 14, 2019 - Opiod prescriptions for pet dogs misused by their masters
January 14, 2019 - People with ASD could be better at recognizing regret and relief in others finds study
January 14, 2019 - Conducting ChIP-Seq with Low Cell Numbers
January 14, 2019 - Study explores support and social networks of family carers of people with dementia
January 14, 2019 - At Risk for an Opioid OD? There’s an App for That
January 14, 2019 - Single national electronic health record will help improve care in Canadian hospitals
January 14, 2019 - Study unearths Britain’s first speech therapists
January 14, 2019 - Study reveals nuances of racial inequalities in breast cancer prevention
January 14, 2019 - Air pollution can raise the risk of miscarriage among women finds study
Scientists receive $5.1 million grant to develop stem cell-based therapy for blinding retinal conditions

Scientists receive $5.1 million grant to develop stem cell-based therapy for blinding retinal conditions

image_pdfDownload PDFimage_print

Scientists at the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research and the Stein Eye Institute have been awarded a $5.1 million grant from the California Institute for Regenerative Medicine to advance the development of a novel therapy for blinding retinal conditions.

The award by the California Institute for Regenerative Medicine, or CIRM, will support the development of a treatment that will use patients’ own skin cells to generate autologous induced pluripotent stem cells to derive retinal pigment epithelium cells, which are lost in many blinding eye conditions. The team, led by Dr. Steven Schwartz, will use the grant to drive the promising therapy to the next critical step toward a clinical trial in humans, submitting an investigational new drug application to the Food and Drug Administration.

“We’re grateful to CIRM and the people of California for this grant, which will allow our team to translate our research into a treatment for major causes of untreatable blindness such as macular degeneration,” said Schwartz, Ahmanson professor of ophthalmology and chief of the retina division at the UCLA Stein Eye Institute. “This pivotal investment brings hope to countless patients and families suffering with blinding eye disease.”

Retinal diseases affecting the center of vision, also called maculopathies, are the leading cause of blindness in the developed world and affect more than 10 percent of the U.S. population over 65. The number of people affected by this untreatable group of disorders, such as age related and myopic macular degeneration, and Stargardt’s macular dystrophy, is expected to increase to nearly 20 million in the nation by 2020.

Although disorders in this group can have varied underlying causes, they are all linked to the deterioration of the layer of retinal pigment epithelium cells beneath the retina, which lines the inner surface of the back of the eye. These cells are critical to vision; they maintain function of light-sensitive cells called photoreceptors, or rods and cones. Without the retinal pigment epithelium cells, the rods and cones cannot survive. Ultimately, the deterioration of these cells leads to the loss of photoreceptors and eventually to blindness.

The induced pluripotent stem cells maintain the genetic code of the individual from whom they originated. The cells also bear none of the hallmarks of age and instead appear much like very young cells. In the research, these induced pluripotent stem cells will be differentiated into a large volume of the patient’s own retinal pigment epithelium cells — between 50,000 and 500,000 — which will then be surgically transplanted into their own retinas. Pre-clinical research suggests these new cells will integrate with the patients’ remaining retinal pigment epithelium cells, rescue related eye tissue and spur regeneration of the surrounding tissue. Thus, these transplants may preserve or restore vision.

Replacing retinal pigment epithelium cells lost to disease with the stem cell-based cells has already been tested in a first-of-its-kind clinical trial led by Schwartz. That trial showed that retinal pigment epithelium cell replacement strategies are safe and possibly effective in addressing retinal blindness. However, these earlier trials used cells created from human embryonic stem cells, which require that patients take drugs that suppress the immune system longer term so that their bodies do not reject the foreign cells. These immunosuppressive drugs carry substantial health risks, particularly for the elderly.

By creating retinal pigment epithelium cells from patient-derived induced pluripotent stem cells, the new method developed by Schwartz and his team should not pose a risk that the cell therapy will be rejected by the patient’s immune system, thus likely eliminating the need for immune suppression. Because many maculopathies are age-related, this key improvement may make Schwartz’s novel treatment more accessible to the individuals who need it most.

Another difference between Schwartz’s method and previously studied treatments is that the new retinal pigment epithelium cells will be delivered to patients suspended in liquid rather than on a scaffold. This makes it possible for the treatment to be administered in a minimally invasive transplant surgery, which reduces risks and provides faster recovery time.

These two advantages open up the possibility of administering the cell therapy earlier in the course of macular diseases, when some functional tissue remains. Early intervention could be critical to the success of treatments for maculopathies because when diseased retinal pigment epithelium cells are lost, neighboring and essential tissues such as photoreceptors are compromised or disappear completely.

“We hope this research will improve upon the methods studied in previous trials, which showed promise but came with drawbacks and risks,” Schwartz said. “The project holds the possibility of developing a treatment that will preserve vision in patients with an early diagnosis, restore vision in patients with end-stage loss of vision, and carry fewer risks.”

Schwartz is developing this treatment in collaboration with a multi-disciplinary team comprised of stem cell biologists, ophthalmologists, retinal biologists, immunologists, transplant surgeons, bioengineers and regulatory experts. This group includes co-investigators Dr. Donald Kohn, professor of microbiology, immunology and molecular genetics, pediatrics and molecular and medical pharmacology; William Lowry, professor of molecular, cell and developmental biology; Jerome Zack, professor and chair of microbiology, immunology and molecular genetics; David Williams, professor of ophthalmology and neurobiology; Saravanan Karumbayaram, adjunct professor of microbiology, immunology and molecular genetics; and Zoran Galic, an associate professor of medicine, all members of the UCLA Broad Stem Cell Research Center; as well as Xiaoyang Wang, assistant professor of medicine and health services research.

This research is supported by the California Institute for Regenerative Medicine-funded UCLA-UCI Alpha Stem Cell Clinic and the UCLA Broad Stem Cell Research Center. This includes previous support from the Esther B. O’Keeffe Foundation, the Jean Perkins Foundation and the UCLA department of ophthalmology, which has support from Research to Prevent Blindness Inc., Louis & Harold Price Foundation, Lavery Foundation, and the Smidt Family Foundation.

The potential cell-based treatment for blinding retinal conditions is used in pre-clinical tests only and has not been tested in humans or approved by the Food and Drug Administration as safe and effective for use in humans.

Source:

https://stemcell.ucla.edu/news/51-million-grant-will-fund-research-develop-stem-cell-based-therapy-blinding-eye-conditions

Tagged with:

About author

Related Articles